Impact of interim progression during the surgery-to-radiotherapy interval and its predictors in glioblastoma treated with temozolomide-based radiochemotherapy |
| |
| Authors: | Chan Woo Wee Eunji Kim Tae Min Kim Chul-Kee Park Jin Wook Kim Seung Hong Choi Roh-Eul Yoo Soon-Tae Lee Il Han Kim |
| |
| Affiliation: | 1.Department of Radiation Oncology,Seoul National University College of Medicine,Seoul,Republic of Korea;2.Department of Internal Medicine,Seoul National University College of Medicine,Seoul,Republic of Korea;3.Department of Neurosurgery,Seoul National University College of Medicine,Seoul,Republic of Korea;4.Department of Radiology,Seoul National University College of Medicine,Seoul,Republic of Korea;5.Department of Neurology,Seoul National University College of Medicine,Seoul,Republic of Korea;6.Cancer Research Institute,Seoul National University College of Medicine,Seoul,Republic of Korea;7.Institute of Radiation Medicine,Seoul National University College of Medicine,Seoul,Republic of Korea |
| |
| Abstract: | ![]()
This study was designed to investigate the impact of interim progression of disease (PD) during the surgery-to-radiotherapy interval (SRI) and its predictors in glioblastoma based on MRIs. A total of 222 patients were planned for radiotherapy (RT) and 166 of them were evaluable for the presence of interim PD by 2 separate MRIs. The size criteria from the updated Response Assessment in Neuro-Oncology criteria was adopted to determine interim PD. 32 (19.3%) patients experienced interim PD, and their median survival (MS) was shorter than patients without PD in univariate (11.3 vs. 19.6 months, p?
|
| |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ |
|
